LANDMARK LEGISLATION
Healthcare provisions in the Inflation Reduction Act
Article
Get an overview of the law's main changes to Medicare and other healthcare markets, and a timeline for implementation.
Read the articleWEBINAR
Get an overview of the law's main changes to Medicare and other healthcare markets, and a timeline for implementation.
Watch the webinarWHITE PAPER
The Inflation Reduction Act requires drug manufacturers to negotiate prices with the federal government, a change with wide-ranging implications for the pharmaceutical industry and healthcare payers.
View the paper
Deeper discounts in the latest round of negotiated prices for Medicare Part D drugs may indicate how future negotiations will play out.
What state Medicaid programs should know and do ahead of the January 2026 launch
Biosimilars recently have made significant strides toward greater acceptance and utilization since their first U.S. approval in 2015, although challenges persist.
We dive into ramifications of the Inflation Reduction Act on out-of-pocket spending limits for health insurance markets and Medicare Part D.
The 2025 national average Part D direct subsidy (DS) will increase to $142.67 as plan sponsors take on additional Part D risk in 2025.
Medicare Advantage organizations (MAOs) will experience another material model change in 2025—this time for Part D.
Plan sponsors seeking creditable coverage for their retiree prescription drug plans may need to enrich coverage in 2025, due to effects from the Inflation Reduction Act (IRA).
We discuss how the Inflation Reduction Act could affect Medicare Part D plans, members, the government, and pharmaceutical manufacturers.
We examine potential ramifications of the Inflation Reduction Act, which may drive the biggest changes in prescription drug coverage since Medicare Part D.
Understanding how the IRA lets beneficiaries smooth their cost sharing over the plan year.
